Extending Use of Biomarkers to Pediatric Population with TBI
Researchers and clinicians hope to make using biomarkers to diagnose TBI in infants or even in pre-natal cord blood a reality.
See more videos with Dr. Ronald Hayes.
More importantly, and what's closer to my heart, is extending this to the pediatric and neonatal population. It's not a major medical problem, but it is such an obscene event that you'd like to do anything you can to avoid that. It's very difficult to diagnose. The kids can't talk, obviously. Biomarkers can help deal with that problem. We're very excited about moving in that, and of course, the FDA approves the biomarkers for adults, but we want to extend it to kids, so the pediatric population. And then one I think that is probably dearest to me, I remember when my youngest son was born, and he aspirated meconium, and you just are a changed person after that. He did fine, but he was in the ER and the ICU for an extended period of time, and there was no way to know how his brain was doing, but we will extend that to the neonatal population. We're working with hypoxic ischemic encephalopathy now. Our goal is actually to be able to test cord blood at birth, and so what does every parent want to know? What does every mother and father--"Is my baby okay?" We do an Apgar test now, but it's like the Glasgow Coma Scale. It's very crude, so if you know the child has been challenged and may be developmentally delayed, there's a lot you can do. And I think that will happen easily within the next 10 years.
Posted on BrainLine April 2, 2013.
Ronald Hayes, PhD is a co-founder and president of Banyan Biomarkers, Inc. He is director of Banyan’s Clinical Programs and Banyan Laboratories.
Produced by Brian King, Vicky Youcha, and Erica Queen, BrainLine.